Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 13;145(7):658-660.
doi: 10.1182/blood.2024027671.

Heme fuels venetoclax resistance in multiple myeloma

Mariateresa Fulciniti  1
Affiliations
Editorial

Heme fuels venetoclax resistance in multiple myeloma

Mariateresa Fulciniti. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Comment on

References

    1. Nair R, Vu AH, Freer AK, et al. Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis. Blood. 2025;145(7):732–747. - PubMed
    1. Bajpai R, Sharma A, Achreja A, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nat Commun. 2020;11(1):1228. - PMC - PubMed
    1. Lin KH, Xie A, Rutter JC, et al. Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity. Cell Metabol. 2019;29(5):1217–1231.e7. - PMC - PubMed
    1. Guièze R, Liu VM, Rosebrock D, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36(4):369–384.e13. - PMC - PubMed
    1. Bajpai R, Matulis SM, Wei C, et al. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax. Oncogene. 2016;35(30):3955–3964. - PMC - PubMed

LinkOut - more resources